New weight loss pill HRS9531 enters final testing phase

NCT ID NCT07670884

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests whether HRS9531 tablets can help overweight or obese adults lose weight over 52 weeks. About 425 participants will receive either the drug or a placebo. The study measures weight change and the proportion of people losing at least 5% of their body weight.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

HRS9531 tablet

What this could lead to

If successful, this could provide a new medication option for significant weight loss in people who are overweight or obese.

What could go wrong

This is a phase 3 trial, but results are not yet available. The drug may cause side effects or not work better than placebo. Long-term safety and effectiveness are still unknown.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC MANAGEMENT OF BODY WEIGHT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Henan Provincial People's Hospital

    Zhengzhou, Henan, 450003, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Nanjing Drum Tower hospital

    Nanjing, Jiangsu, 210008, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact